teaser
UK-based late-stage clinical trials specialist Synexus has announced it is expanding the scope of its drug trials in the UK, mainland Europe and beyond.
The firm will increase its phase IV (postmarketing surveillance) trials after running a series of successful studies for major drug companies.
Regulatory authorities are increasingly demanding phase IV trials to look at use in populations not covered by the original trials (children and pregnant women), to consider the effects of drug interactions, and to try to detect any rare or long-term side-effects.
The firm’s model removes takes the onus of running trials away from doctors – an issue which has caused difficulties in recruiting – by dealing directly with patients and compiling detailed reports on the trial for each physician.
Patient recruitment will take place around the firm’s 14 hub sites in the UK, Poland, Hungary, Bulgaria, South Africa and India.
Chris Hannigan, executive vice-president of Synexus, said: “We have put together a model where the patient’s GP receives more information on the trial than ever before, without having to squeeze trial appointments into an already overcrowded diary.”
Copyright © PA Business 2008
